Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosaccharide and Nucleoside Supplements in CDG
NCT02511041Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of n-acetyl-d-glucosamine and uridine in congenital disorder of glycosylation (CDG), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Absolute Lymphocyte Count. Started Jun 2015; status: terminated.
02
Drugs
n-acetyl-d-glucosamineuridine
03
Conditions
congenital disorder of glycosylation (CDG)
Beyond the preview
Go deeper on NCT02511041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511041.